Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: Enhancement of mucosal and systemic immune response

Drug Delivery

Volumn 23, Issue 1, 2016, Pages 185-194

  Pawar, Dilip ^a,b   Jaganathan, K S ^b  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b Shantha Biotechnics Limited   (India)

Author keywords

Glycol chitosan; hepatitis B surface antigen; mucosal immunization; nanoparticles; vaccine

Indexed keywords

CHITOSAN NANOPARTICLE; GAMMA INTERFERON; GLYCOL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MUCIN; CHITOSAN; GLYCOL-CHITOSAN; HEPATITIS ANTIBODY; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; TISSUE ADHESIVE;

ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZE DRYING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUCOADHESION; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; VACCINATION; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; IMMUNITY; INTRANASAL DRUG ADMINISTRATION; MALE; RABBIT; SOLUBILITY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHITOSAN; DRUG DELIVERY SYSTEMS; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY; IMMUNITY, MUCOSAL; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; RABBITS; SOLUBILITY; TISSUE ADHESIVES;

EID: 84954309205     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.908427     Document Type: Article

References (52)

1. Slütter B, Hagenaars N, Jiskoot W. (2008). Rational design of nasal vaccines. J Drug Target 16:1-17.
2. Jain S, Khomane K, Jain AK, Dani P. (2011). Nanocarriers for transmucosal vaccine delivery. Current Nanoscience 7:160-77.
3. Vajdy M, O'Hagan DT. (2001). Microparticles for intranasal immunization. Adv Drug Del Rev 51:127-41.
4. Borges O, Lebre F, Bento D, et al. (2010). Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res 27:211-23.
5. Felt O, Buri P, Gurny R. (1998). Chitosan: A unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24:979-93.
6. Illum L, Farraj NF, Davis SS. (1994). Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186-9.
7. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11:1358-61.
8. Kotzé AF, Thanou MM, Luessen HL, et al. (1999). Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur J Pharm Biopharm 47: 269-74.
9. Arca HC, Günbeyaz M, Senel S. (2009). Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 8:937-53.
10. Mourya VK, Inamdar NN. (2008). Chitosan-modifications and applications: opportunities galore. React Funct Polymer 68:1013-51.
11. Werle M, Takeuchi H, Bernkop-Schnürch A. (2009). Modified chitosans for oral drug delivery. J Pharm Sci 98:1643-56.
12. Gogev S, de Fays K, Versali MF, et al. (2004). Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1. Vaccine 22:1946-53.
13. Trapania A, Sitterberg J, Bakowsky U, Kissel T. (2009). The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs. Int J Pharm 375:97-106.
14. Mangal S, Pawar D, Garg NK, et al. (2011). Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine 29:4953-62.
15. Sadeghi AM, Dorkoosh FA, Avadi MR, et al. (2008). Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. Int J Pharm 355:299-306.
16. Mao S, Bakowsky U, Jintapattanakit A, Kissel T. (2006). Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J Pharm Sci 95:1035-48.
17. Mao S, Germershaus O, Fischer D, et al. (2005). Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm Res 22:2058-68.
18. Jaganathan KS, Singh P, Prabakaran D, et al. (2004). Development of a single-dose stabilized poly(d,l-lactic-co-glycolic acid) microspheresbased vaccine against hepatitis B. J Pharm Pharmacol 56:1243-50.
19. Pawar D, Mangal S, Goswami R, Jaganathan KS. (2013). Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm 85: 550-9.
20. Borges O, Borchard G, Verhoef JC, et al. (2005). Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299:155-66.
21. Amidi M, Romeijn SG, Borchard G, et al. (2006). Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release 111:107-16.
22. Mathia NR, Timoszyk J, Stetsko PI, et al. (2002). Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target 10: 31-40.
23. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
24. Pawar D, Goyal AK, Mangal S, et al. (2010). Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 12:130-7.
25. He P, Davis SS, Illum L. (1998). In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm 166:75-88.
26. Debin A, Kravtzoff R, Santiago JV, et al. (2002). Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20:2752-63.
27. Jain S, Singh P, Mishra V, Vyas SP. (2005). Mannosylated niosomes as adjuvantcarrier system for oral genetic immunization against hepatitis B. Immunol Lett 101:41-9.
28. Sachdeva S, Ahmad G, Malhotra P, et al. (2004). Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 119 and 42 kDa fragments expressed in Escherichia coli. Infect Immun 70:5775-85.
29. Prego C, Paolicelli P, Díaz B, et al. (2010). Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 28: 2607-14.
30. Amidi M, Romeijn SG, Verhoef JC, et al. (2007). N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25:144-53.
31. Florea BI, Meaney C, Junginger HE, Borchard G. (2002). Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSci 4:E12. doi: 10.1208/ps040312.
32. Jaganathan KS, Vyas SP. (2006). Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24: 4201-11.
33. Soane RJ, Hinchcliffe M, Davis SS, Illum L. (2001). Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 217:183-91.
34. Illum L. 2003. Nasal drug delivery-possibilities problems and solutions. J Control Release 87:187-98.
35. Eldridge JH, Hammond CJ, Meulbroek JA, et al. (1990). Controlled vaccine release in the gut associated lymphoid tissues, I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 11:205-14.
36. Neutra MR, Kozlowski PA. (2006). Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 6:148-58.
37. Zeitlin L, Cone RA, Whaley KJ. (1999). Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 5:54-64.
38. Köping-Höggard M, Sánchez A, Alonso MJ. (2005). Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 4:185-96.
39. Vila A, Sánchez A, Evora C, et al. (2005). PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm 292: 43-52.
40. Smart JD. (2005). The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 57:1556-68.
41. Peppas NA, Buri PA. (1985). Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Release 2:257-75.
42. Synman D, Hamman JH, Kotzé JS, et al. (2002). The relationship between the absolute molecular weight and the degree of quaternization of N-trimethyl chitosan chloride. Carbohydr Polym 50:145-50.
43. Soane RJ, Frier M, Perkins AC, et al. (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178: 55-65.
44. Delie F. (1998). Evaluation of nano-and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev 34:221-33.
45. Slütter B, Bal S, Keijzer C, et al. (2010). Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28:6282-91.
46. Slütter B, Bal SM, Que I, et al. (2010). Antigen adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol Pharm 7:2207-15.
47. McNabb PC, Tomasi TB. (1981). Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol 35:477-96.
48. Renegar KB, Small Jr PA. (1991). Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146:1972-8.
49. Isaka M, Yasuda Y, Mizokami M, et al. (2001). Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19:1460-6.
50. Coombes AG, Lavelle EC, Jenkins PG, Davis SS. (1996). Single dose, polymeric, microparticle-based vaccines: The influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 14:1429-38.
51. Jabbal-Gill I, Lin W, Jenkins P, et al. (1999). Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18:238-50.
52. Jenkins PG, Coombes AG, Yeh MK, et al. (1995). Aspects of the design and delivery of microparticles for vaccine applications. J Drug Target 3:79-81.